These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37087120)

  • 1. Reply to the Letter to the Editor From He Y et al.
    Okubo Y; Yatabe Y
    J Thorac Oncol; 2023 May; 18(5):e46-e48. PubMed ID: 37087120
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the Letter to the Editor From Zhou et al.
    Dagogo-Jack I; Mino-Kenudson M
    J Thorac Oncol; 2020 Aug; 15(8):e136-e137. PubMed ID: 32718538
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to the Letter to the Editor by Hendriks et al.
    Eberhardt WE; Mitchell A; Rami-Porta R
    J Thorac Oncol; 2016 Mar; 11(3):e43-4. PubMed ID: 26922925
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to the letter to the editor 'Ablative therapies for lung metastases: a need to acknowledge the efficacy and toxicity of stereotactic ablative body radiotherapy' by Siva et al.
    de Baère T; Aupérin A; Deschamps F; Chevallier P; Gaubert Y; Boige V; Fonck M; Escudier B; Palussiére J
    Ann Oncol; 2015 Oct; 26(10):2196-7. PubMed ID: 26193885
    [No Abstract]   [Full Text] [Related]  

  • 5. Authors reply to letter to the editor by Dr Degens et al.
    Bommart S; Pujol JL; Coffy A; Daurès JP; Roch B
    Lung Cancer; 2021 Mar; 153():185. PubMed ID: 33461818
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to the letter to the editor 'Flaws in the trial design of IFCT-0802' by Gyawali et al.
    Pujol JL; Morin F; Zalcman G;
    Ann Oncol; 2015 Oct; 26(10):2199. PubMed ID: 26254441
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to the letter to the editor 'How much evidence isn't in evidence-based guidelines?' by Johnson et al.
    Cherny NI; Kloke M; Cervantes A; Pentheroudakis G;
    Ann Oncol; 2016 Mar; 27(3):550-1. PubMed ID: 26602775
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.
    Beau-Faller M; Cadranel J
    Ann Oncol; 2016 Feb; 27(2):359-60. PubMed ID: 26658890
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to "Letter to the Editor" From David Y. Mak et al.
    Kenmotsu H; Mori K; Nakagawa K; Yamamoto N; Takahashi T
    J Thorac Oncol; 2023 Jan; 18(1):e4-e5. PubMed ID: 36543438
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to: Letter to the Editor: Comment on ''Radiomics with Artificial Intelligence for the Prediction of Early Recurrence in Patients with Clinical Stage IA Lung Cancer'' by Usuzaki, Takuma et al.
    Shimada Y
    Ann Surg Oncol; 2023 Feb; 30(2):914-915. PubMed ID: 36376570
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al.
    Pietrantonio F; Cremolini C
    Ann Oncol; 2015 Nov; 26(11):2353. PubMed ID: 26347099
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to the letter to the editor 'KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC' by Robles et al.
    Lee SY; Choi JE; Park JY
    Ann Oncol; 2016 Feb; 27(2):361-3. PubMed ID: 26578724
    [No Abstract]   [Full Text] [Related]  

  • 13. In reply to the letter to the editor 'in Reply to Gandaglia et al.' by De Bari et al.
    Gandaglia G; Karakiewicz PI; Briganti A; Menon M; Sun M; Abdollah F
    Ann Oncol; 2014 Sep; 25(9):1862-1863. PubMed ID: 24914042
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to the letter to the editor 'ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer' by Uguen et al.
    Ilie M; Hofman P
    Ann Oncol; 2015 Aug; 26(8):1802. PubMed ID: 25957328
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to the Waalkes et al., Letter to the editor concerning our "letter to the editor, Re: Lung tumors in mice induced by "whole-life" inorganic arsenic exposure at human relevant doses, Waalkes et al., Arch Toxicol, 2014".
    Cohen SM; Arnold LL; Klaunig JE; Goodman JI
    Arch Toxicol; 2015 Nov; 89(11):2167-8. PubMed ID: 26449479
    [No Abstract]   [Full Text] [Related]  

  • 16. reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al.
    Lacouture ME;
    Ann Oncol; 2016 Nov; 27(11):2138-2139. PubMed ID: 27664149
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to "Letter to the editor of Annals of Surgical Oncology Concerning " The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer" by Sunil Kumar et al.
    Eby M; Seder CW
    Ann Surg Oncol; 2021 Jun; 28(6):3433-3434. PubMed ID: 33106974
    [No Abstract]   [Full Text] [Related]  

  • 18. In reply to Li et al. Letter to the editor. "Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.".
    Viani GA; Gouveia AG; Moraes FY
    Radiother Oncol; 2022 Dec; 177():245-246. PubMed ID: 36265684
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Letter to the Editor: P. van Damme et al., Vaccine 34 (2016) 757-761, as a reply to Ryser et al's letter in Vaccine.
    Van Damme P; Stanley M
    Vaccine; 2016 Aug; 34(36):4272. PubMed ID: 27452650
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Alizadeh's Letter to the Editor Re: Lu, P.Y. et al., Nutrients 2017, 9, 38.
    Lu PY; Shu L; Shen SS; Chen XJ; Zhang XY
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28686193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.